metformin has been researched along with Osteoporotic Fractures in 9 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Osteoporotic Fractures: Breaks in bones resulting from low bone mass and microarchitectural deterioration characteristic of OSTEOPOROSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the metformin effect on the risk of osteoporosis (OS) and/or vertebral fracture (VF)." | 8.02 | Metformin use is associated with a lower risk of osteoporosis/vertebral fracture in Taiwanese patients with type 2 diabetes mellitus. ( Tseng, CH, 2021) |
| " We aimed to investigate the risk of major osteoporotic fractures (MOF) with SGLT2 inhibitors compared to glucagon-like peptide 1 (GLP-1) receptor agonists when used as add-on therapies to metformin." | 4.12 | SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: A nationwide cohort study. ( Al-Mashhadi, ZK; Gregersen, S; Starup-Linde, J; Vestergaard, P; Viggers, R, 2022) |
| " We aimed to investigate the risk of major osteoporotic fractures (MOF) for treatment with GLP-1RA compared to dipeptidyl peptidase 4 inhibitors (DPP-4i) as add-on therapies to metformin." | 4.12 | The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors: A Danish nationwide cohort study. ( Al-Mashhadi, ZK; Fuglsang-Nielsen, R; Gregersen, S; Starup-Linde, J; Vestergaard, P; Viggers, R, 2022) |
| "To investigate the metformin effect on the risk of osteoporosis (OS) and/or vertebral fracture (VF)." | 4.02 | Metformin use is associated with a lower risk of osteoporosis/vertebral fracture in Taiwanese patients with type 2 diabetes mellitus. ( Tseng, CH, 2021) |
| "To assess the proportion of members of a private health insurance at the Hospital Italiano de Buenos Aires with primary adherence to, 1) bisphosphonates for secondary prevention of osteoporotic fractures, 2) insulin and metformin in type 2 diabetes, and 3) tamoxifen in the context of treatment of breast cancer." | 3.88 | [Evaluation of primary adherence to medications in patients with chronic conditions: A retrospective cohort study]. ( Esteban, S; Peper, FE; Terrasa, SA, 2018) |
| " placebo in combination with different insulin regimens (the Copenhagen Insulin and Metformin Therapy trial) in patients with T2DM." | 2.87 | The effect of metformin versus placebo in combination with insulin analogues on bone mineral density and trabecular bone score in patients with type 2 diabetes mellitus: a randomized placebo-controlled trial. ( Almdal, TP; Boesgaard, TW; Breum, L; Eiken, P; Gade-Rasmussen, B; Gluud, C; Hemmingsen, B; Jensen, T; Krarup, T; Lund, SS; Lundby-Christensen, L; Madsbad, S; Mathiesen, ER; Nordklint, AK; Perrild, H; Sneppen, SB; Tarnow, L; Thorsteinsson, B; Vestergaard, H; Vestergaard, P, 2018) |
| "Patients with type 2 diabetes mellitus (T2DM) have an increased risk of fragility fractures, to which antidiabetic therapies may contribute." | 1.48 | Real-world antidiabetic drug use and fracture risk in 12,277 patients with type 2 diabetes mellitus: a nested case-control study. ( Ali, MS; Díez-Pérez, A; Losada, E; Martínez-Laguna, D; Mauricio, D; Nogués, X; Prieto-Alhambra, D; Puig-Domingo, M; Soldevila, B, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Mashhadi, ZK | 2 |
| Viggers, R | 2 |
| Starup-Linde, J | 2 |
| Vestergaard, P | 3 |
| Gregersen, S | 2 |
| Fuglsang-Nielsen, R | 1 |
| Tseng, CH | 1 |
| Peper, FE | 1 |
| Esteban, S | 1 |
| Terrasa, SA | 1 |
| Losada, E | 1 |
| Soldevila, B | 1 |
| Ali, MS | 1 |
| Martínez-Laguna, D | 1 |
| Nogués, X | 1 |
| Puig-Domingo, M | 1 |
| Díez-Pérez, A | 1 |
| Mauricio, D | 1 |
| Prieto-Alhambra, D | 1 |
| Nordklint, AK | 1 |
| Almdal, TP | 1 |
| Lundby-Christensen, L | 1 |
| Boesgaard, TW | 1 |
| Breum, L | 1 |
| Gade-Rasmussen, B | 1 |
| Sneppen, SB | 1 |
| Gluud, C | 1 |
| Hemmingsen, B | 1 |
| Jensen, T | 1 |
| Krarup, T | 1 |
| Madsbad, S | 1 |
| Mathiesen, ER | 1 |
| Perrild, H | 1 |
| Tarnow, L | 1 |
| Thorsteinsson, B | 1 |
| Vestergaard, H | 1 |
| Lund, SS | 1 |
| Eiken, P | 1 |
| Salari-Moghaddam, A | 1 |
| Sadeghi, O | 1 |
| Keshteli, AH | 1 |
| Larijani, B | 1 |
| Esmaillzadeh, A | 1 |
| Antonopoulou, M | 1 |
| Bahtiyar, G | 1 |
| Banerji, MA | 1 |
| Sacerdote, AS | 1 |
| Josse, RG | 1 |
| Majumdar, SR | 1 |
| Zheng, Y | 1 |
| Adler, A | 1 |
| Bethel, MA | 1 |
| Buse, JB | 1 |
| Green, JB | 1 |
| Kaufman, KD | 1 |
| Rodbard, HW | 1 |
| Tankova, T | 1 |
| Westerhout, CM | 1 |
| Peterson, ED | 1 |
| Holman, RR | 1 |
| Armstrong, PW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Metformin Versus Placebo, Including Three Insulin-Analogue Regimens With Variating Postprandial Glucose Regulation, on CIMT in T2DM Patients - A Randomized, Multicenter Trial[NCT00657943] | Phase 4 | 415 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for metformin and Osteoporotic Fractures
| Article | Year |
|---|---|
Metformin use and risk of fracture: a systematic review and meta-analysis of observational studies.
Topics: Humans; Hypoglycemic Agents; Metformin; Observational Studies as Topic; Osteoporotic Fractures; Risk | 2019 |
Diabetes and bone health.
Topics: Bone and Bones; Bone Density; Diabetes Complications; Diabetes Mellitus; Humans; Hypoglycemic Agents | 2013 |
2 trials available for metformin and Osteoporotic Fractures
| Article | Year |
|---|---|
The effect of metformin versus placebo in combination with insulin analogues on bone mineral density and trabecular bone score in patients with type 2 diabetes mellitus: a randomized placebo-controlled trial.
Topics: Adult; Aged; Bone Density; Cancellous Bone; Diabetes Mellitus, Type 2; Double-Blind Method; Drug The | 2018 |
Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.
Topics: Age Factors; Aged; Blood Preservation; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blin | 2017 |
5 other studies available for metformin and Osteoporotic Fractures
| Article | Year |
|---|---|
SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: A nationwide cohort study.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Humans; Metformin; Oste | 2022 |
The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors: A Danish nationwide cohort study.
Topics: Cohort Studies; Denmark; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Lik | 2022 |
Metformin use is associated with a lower risk of osteoporosis/vertebral fracture in Taiwanese patients with type 2 diabetes mellitus.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Incidence; | 2021 |
[Evaluation of primary adherence to medications in patients with chronic conditions: A retrospective cohort study].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chronic Disease; Cohort | 2018 |
Real-world antidiabetic drug use and fracture risk in 12,277 patients with type 2 diabetes mellitus: a nested case-control study.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Utilization; Female; | 2018 |